What is ADUHELM™?

ADUHELM is the first and only Alzheimer’s disease treatment to address a defining pathology of the disease by reducing amyloid beta plaques in the brain.

How does it work?

ADUHELM reduces amyloid beta plaques in the brain, which is one of the defining pathologies of Alzheimer’s disease.

Has it been FDA approved?

Yes, ADUHELM has been granted accelerated approval based on data from clinical trials.

What clinical trials did ADUHELM go through?

ADUHELM went through two Phase 3 clinical trials—EMERGE (Study 1) and ENGAGE (Study 2). The trials focused on patients with early stages of Alzheimer’s disease with mild cognitive impairment and mild dementia. Participants had to have confirmed presence of amyloid pathology. In both studies, ADUHELM consistently showed a dose- and time-dependent effect on the lowering of amyloid beta plaques.

Is ADUHELM safe to use?

Yes, ADUHELM’s safety profile was documented in more than 3,000 patients who received at least one dose of ADUHELM.

What side effects can occur for patients taking ADUHELM?

Serious side effects can include amyloid related imaging abnormalities (ARIA), small spots of bleeding in or on the surface of the brain with the swelling, headache, confusion, dizziness, vision changes, nausea, and serious allergic reactions.

What is the indication of ADUHELM?

ADUHELM is taken through intravenous injection.

What is the dosage of ADUHELM?

There are two doses of ADUHELM—170 mg solution and 300 mg in single-dose vials.

How do I know if I can take ADUHELM?

You should talk to your healthcare provider before taking ADUHELM. Your healthcare provider will need to know all of your medical conditions, including if you are or plan on becoming pregnant. You also will need to disclose whether or not you are breastfeeding or plan on breastfeeding.